Navigation Links
Study of placenta unexpectedly leads to cancer gene
Date:12/16/2008

University of Rochester Medical Center scientists discovered a gene mutation that impairs the placenta and also is influential in cancer development, according to a study published online December 16, 2008, in the journal PLoS (Public Library of Science) Biology.

The investigation is the first to link the key placental gene, SENP2, to the well-known p53 protein, which is defective in 50 percent of all cancers.

Until now, the SENP2 gene's role in early embryo development was not known. As a result of making the connection between SENP2 and the potent cancer stimuli, it will be possible to gain more insight into the complex genetic network involved in cancer, and to develop new therapies, said lead author Wei Hsu, Ph.D., associate professor of Biomedical Genetics and Oncology, of the James P. Wilmot Cancer Center.

Hsu and former graduate student Shang-Yi Chiu, currently a postdoctoral fellow at Howard Hughes Medical Institute, Dana-Farber Cancer Institute at Harvard University, have been investigating how cellular signaling triggered by gene mutations affect embryo development in mice. The goal is to better understand the genetic causes and possible treatments for a number of diseases.

"What we discovered was an unexpected interaction between an old player, p53, and a new player, SENP2," said Hsu, who also has an appointment in the URMC Center for Oral Biology.

SENP2 (SUMO-specific protease 2) is highly expressed in trophoblast cells, which are the stem cells required to form the placenta. The placenta surrounds, protects and nourishes the developing fetus. While investigating disruption of placental formation in a mouse model, Hsu's team observed that embryos lacking SENP2 failed to properly make placental tissue.

The failure occurred, researchers discovered, because the cells that give rise to the placental tissues had undergone cell cycle arrest, and were trapped in a state of suspended growth. Next, researchers set out to find SENP2 target proteins that could be involved in arresting cell growth.

In the journey, they discovered that p53 or proteins that modify p53 activity were harmed by the SENP2 deficiency. The consequence was that p53 could no longer perform its vital job as a tumor suppressor. When p53 is functioning normally, it acts as a crucial guardian of the genome, or a checkpoint, by fixing genetic mistakes as they arise.

But when the p53 molecule is aberrantly regulated, either by an outside virus or an inherited genetic abnormality, the risk of cancer is higher because p53 cannot perform its job.

Researchers also found that SENP2 indirectly regulates p53 activity through another protein called Mdm2, which was already known to be involved in some cancers. In cells lacking SENP2, the Mdm2 becomes trapped in the nucleus, and is unable to halt p53, allowing it to accumulate within the cell. This disruption leads to distinct problems in cell cycle progression and normal gene replication.


'/>"/>

Contact: Leslie Orr
Leslie_Orr@urmc.rochester.edu
585-275-5774
University of Rochester Medical Center
Source:Eurekalert

Related biology news :

1. New study pardons the misunderstood egg
2. Ocean fish farming harms wild fish, study says
3. Proactive care saves lives of seniors, study finds
4. Orangutans spontaneous whistling opens new chapter in study of evolution of speech
5. First-ever socioeconomic study on coral reefs points to challenges of coastal resource management
6. Study reveals effects of unconscious exposure to advertisements
7. Rice University study finds possible clues to epilepsy, autism
8. Researchers study virus with unusual properties
9. Nanotechnology culture war possible, says Yale study
10. Gene therapy corrects sickle cell disease in laboratory study
11. USC researchers head global effort to study genetic risks that contribute to psychiatric diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2016)... Calif. , Dec. 15, 2016   WaferGen ... publicly held genomics technology company, announced today that on ... Listing Qualifications Department of The Nasdaq Stock Market LLC ... closing bid price of WaferGen,s common stock had been ... Accordingly, WaferGen has regained compliance with Listing Rule 5550(a)(2) ...
(Date:12/15/2016)... 14, 2016 "Increase in mobile transactions is ... mobile biometrics market is expected to grow from USD ... 2022, at a CAGR of 29.3% between 2016 and ... the growing demand for smart devices, government initiatives, and ... "Software component is expected to grow at a high ...
(Date:12/7/2016)... 2016 According to a new market research report "Emotion ... Expression, Voice Recognition), Service, Application Area, End User, And Region - Global Forecast ... USD 6.72 Billion in 2016 to USD 36.07 Billion by 2021, at a ... Reading ... MarketsandMarkets Logo ...
Breaking Biology News(10 mins):
(Date:1/18/2017)... ... January 18, 2017 , ... DrugDev ... for Clinical Ops Executives (Hyatt Regency Miami, January 24-26). DrugDev will join customers ... research issues such as trial performance metrics, patient enrollment diversity, protocol optimization, and ...
(Date:1/18/2017)... ... January 18, 2017 , ... ... of the latest paper by its Science Editor, Dr. Elisabeth Bik, in the ... Medische Microbiologie). Dr. Bik joined uBiome in October 2016 from her previous position ...
(Date:1/18/2017)... 2017 Shareholder rights law firm Johnson & ... board members of CoLucid Pharmaceuticals, Inc. (NASDAQ: ... the proposed sale of the Company to Eli Lilly ... small molecules for the acute treatment of migraines. ... signed a definitive merger agreement with Eli Lilly. Under ...
(Date:1/18/2017)... 2017  Caris Life Sciences, a leading innovator ... largest private funder of pancreatic cancer research, are ... impact of immunotherapy in the treatment of pancreatic ... to identify potential trial candidates based on biomarker ... and study investigators. The Lustgarten Foundation is a ...
Breaking Biology Technology: